Covered recipient · General Payments record
CHERISSE LOHELANI SEN KAWAMURA
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2025
$539.93
- Reported across 18 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $495.62 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $235.62 | 8 |
| Novo Nordisk AS | $137.87 | 3 |
| ABBVIE INC. | $100.04 | 4 |
| Lilly USA, LLC | $22.09 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Ordering applied by this site (paying entity, then date) · record values are shown as CMS published them
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $33.61 | 05/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202170795 | CMS |
| ABBVIE INC. | $24.08 | 06/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202170797 | CMS |
| ABBVIE INC. | $19.50 | 07/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202170799 | CMS |
| ABBVIE INC. | $22.85 | 09/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202170801 | CMS |
| Gilead Sciences, Inc. | $7.32 | 05/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234594040 | CMS |
| Gilead Sciences, Inc. | $7.98 | 07/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234592010 | CMS |
| Gilead Sciences, Inc. | $20.80 | 07/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234520171 | CMS |
| Gilead Sciences, Inc. | $6.08 | 09/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234598530 | CMS |
| Gilead Sciences, Inc. | $22.17 | 10/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234503279 | CMS |
| Gilead Sciences, Inc. | $134.99 | 11/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234378968 | CMS |
| Gilead Sciences, Inc. | $4.55 | 12/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234603998 | CMS |
| Gilead Sciences, Inc. | $31.73 | 12/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234429328 | CMS |
| Lilly USA, LLC | $22.09 | 04/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186546682 | CMS |
| Novo Nordisk Inc | $17.81 | 03/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188382093 | CMS |
| Novo Nordisk Inc | $96.89 | 05/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188144701 | CMS |
| Novo Nordisk Inc | $23.17 | 06/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188424892 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2021 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.